Leiomyosarcoma - 03/10/13
Doi : 10.1016/j.hoc.2013.07.002
César Serrano, MD a, b, Suzanne George, MD b, ⁎ 
a Fletcher Laboratory, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Thorn 528, Boston, MA 02115, USA
b Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
∗Corresponding author.
Résumé |
This article presents an overview of the current literature about the biology, pathology, and the clinical management of leiomyosarcoma. In addition, the article emphasizes and discusses the current systemic treatment options available for patients with leiomyosarcoma, which range from cytotoxic chemotherapy to target therapies. Particular leiomyosarcoma subtypes, such as uterine leiomyosarcoma and inferior vena cava leiomyosarcoma, are discussed separately.
Le texte complet de cet article est disponible en PDF.Keywords : Leiomyosarcoma, Chemotherapy, Targeted therapy, Prognostic factors, Uterine leiomyosarcoma
Plan
| Funding Sources: Spanish Society of Medical Oncology (SEOM) Translational Award (C. Serrano); Driscoll Family Leiomyosarcoma Research Fund (S. George). |
|
| Conflict of Interest: Nil. |
© 2013
Elsevier Inc. Tous droits réservés.
Vol 27 - N° 5
P. 957-974 - octobre 2013 Retour au numéro
Article précédent
- Liposarcomas
- Joern Henze, Sebastian Bauer
- Angiosarcomas and Other Sarcomas of Endothelial Origin
- Angela Cioffi, Sonia Reichert, Cristina R. Antonescu, Robert G. Maki
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?